id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-352905-ge3u32hm	Galimberti, Sara	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2	2020-09-02		.txt	text/plain	5383	231	45	Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1. Translated in the COVID-19 context, if TKIs would sustain the coronavirus infection or replication, we might expect to observe a significant increase of TTV load during treatment of our patients with nilotinib. In the second phase of our study, we employed the NanoString technology for analyzing the expression of 770 inflammationand immunity-related genes in five CML patients before and after 6 months of treatment with imatinib, with the aim of testing the impact of this TKI on the possible immunological control of viral infection. Considering that it has been proven that at diagnosis, the immunity of these patients is severely impaired (63) , the low infection rate observed during the 2020 pandemic could prove that TKIs play an antiviral role or, at least, could not impair the host response against the new coronavirus.	./cache/cord-352905-ge3u32hm.txt	./txt/cord-352905-ge3u32hm.txt